Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Stages of Pulmonary Embolism

By HospiMedica staff writers
Posted on 02 Nov 2005
A new rule classifies patients who have pulmonary embolism into five disease stages that reveal an increasing risk of death or other adverse outcome.

Investigators studied data from 15, 531 discharged patients hospitalized for pulmonary embolism at hospitals in Pennsylvania (USA). More...
They divided the patients into two groups: one to develop the rule and the other to verify their conclusions.

A pulmonary embolism involves a clot that travels through the bloodstream and suddenly blocks an artery of the lung. The most common type begins in either a leg or pelvic vein. Once a clot breaks loose, it tends to travel to the lung. The researchers looked at 11 patient factors independently associated with 30-day patient mortality from pulmonary embolism. These were two demographic factors (age and male sex); three illnesses (cancer, heart failure, and chronic lung disease); and six clinical findings on measurements of pulse, systolic blood pressure, respiratory rate, temperature, altered mental state (disorientation, lethargy, stupor), and arterial oxygen saturation level. Each of these parameters was assigned a numerical score to quantify it with the potential for death.

According to the authors, the rule identifies patients who are at either low or high risk of fatal and nonfatal medical outcomes associated with pulmonary embolism. For example, the 30-day mortality rate for a class I score was 1.6% or less. For class II, it was 3.5%. At class V, it ranged from 10-24.5%. Through outpatient management or early hospital discharge of patients identified as very low risk in class I or low-risk in class II, the rule could save costs without adding risk to the patient, once its usefulness has been confirmed in a prospective study.

The study was led by Drahomir Aujesky of the Centre Hospitalier Universitaire Vadois in Lausanne (Switzerland). The findings were published in the second issue for October 2005 of the American Journal of Respiratory and Critical Care Medicine.


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.